Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: Data from the third interim analysis of opal balance, an open-label, long-term extension study. BMJ Publishing Group Limited.
Citace podle Chicago (17th ed.)Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.
Citace podle MLA (9th ed.)Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.